Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking ago... IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. Mehr anzeigen
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.4 | -16.8674698795 | 8.3 | 8.55 | 6.83 | 240389 | 7.26532616 | CS |
| 4 | -1.61 | -18.9189189189 | 8.51 | 11.62 | 6.83 | 211172 | 8.93158219 | CS |
| 12 | -9.43 | -57.7464788732 | 16.33 | 20.35 | 6.83 | 262140 | 12.81717559 | CS |
| 26 | -0.25 | -3.4965034965 | 7.15 | 22.5 | 6.1721 | 285198 | 12.22169759 | CS |
| 52 | -0.92 | -11.7647058824 | 7.82 | 22.5 | 6.1721 | 296087 | 11.31601094 | CS |
| 156 | -20.94 | -75.2155172414 | 27.84 | 35.98 | 3.81 | 352985 | 16.70890994 | CS |
| 260 | -30.59 | -81.5950920245 | 37.49 | 127.11 | 3.81 | 282613 | 29.41304382 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
